- Autolus Therapeutics plc AUTL has announced new data from AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and r/r Adult Acute Lymphoblastic Leukemia (ALL) trials.
- The data were presented at the European Hematology Association Virtual Congress 2021.
- As of the cut-off date of May 17, obe-cel was well-tolerated and demonstrated a favorable safety profile in adult patients with r/r low-grade B-cell lymphoma, despite a high disease burden.
- All treated patients achieved complete metabolic remission.
- Mild cytokine release syndrome (CRS) was reported in 4 patients and moderate CRS in 1 patient.
- No immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.
- At a median follow-up of 6 months, 8/9 patients were disease-free at last follow-up, with one patient relapsed but was rescued with radiotherapy.
- One patient died of a COVID-19 infection at month 5.6 while in complete metabolic remission.
- In 20 patients in Cohort A with r/r ALL, the therapy was well tolerated, with no patients experiencing severe or higher CRS.
- Three patients, all of whom had high leukemia burden (over 50% blasts), experienced severe ICANS that resolved with steroids.
- Of the 20 patients evaluable for efficacy, 17 patients achieved a minimum residual disease-negative complete remission at one month.
- Across all treated patients, event-free survival (EFS) at twelve months and twenty-four months is 50.2%, with median EFS not being reached.
- The management will host a conference call and webcast today at 8:30 am ET.
- Price Action: AUTL shares are up 0.7% at $6.90 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
